X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Uzpruvo (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.
Lead Product(s): Ustekinumab
Therapeutic Area: Gastroenterology Product Name: Uzpruvo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alvotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
Uzpruvo (ustekinumab) biosimilar candidate to Stelara is a human IgG1κ monoclonal antibody (mAb), which is investigated for the treatment of moderate to severe chronic plaque-type psoriasis.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: Uzpruvo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
Ximluci (ranibizumab) binds and inhibits VEGF-A, including VEGF110, preventing the interaction of VEGF-A with VEGFR1 and VEGFR2 on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Product Name: Ximluci
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Xbrane Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2023
Details:
Hukyndra (adalimumab) is a monoclonal antibody and a biosimilar to Humira® (adalimumab) that inhibits tumor necrosis factor. Adalimumab is first product launched through an exclusive strategic partnership announced by Alvotech and STADA in November 2019.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Hukyndra
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Alvotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
Hukyndra (adalimumab), Hukyndra is a monoclonal antibody and a biosimilar to Humira® (adalimumab) that inhibits tumor necrosis factor, increases availability of high-concentration, low-volume, citrate-free presentations of adalimumab.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Hukyndra
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Alvotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2022
Details:
Nefecon (budesonide) is a patented novel, investigational oral formulation of a potent and well-known active substance – budesonide – for targeted release. The formulation is designed to deliver the drug to the ileum where the Peyer’s patches are concentrated.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Product Name: Nefecon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Calliditas Therapeutics AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
The biosimilar to Humira®, with its 100 mg/mL Hukyndra (adalimumab) in 40 mg/0.4 mL custom-designed pre-filled auto-injector pen as well as 40 mg/0.4 mL and 80 mg/0.8 mL pre-filled syringe presentations, offers a comprehensive range of biosimilar and devices designed.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Hukyndra
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Alvotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
Under the terms of the Agreement, STADA will be responsible for commercializing Pliaglis in the Territories utilizing its experienced sales force.
Lead Product(s): Lidocaine,Tetracaine
Therapeutic Area: Neurology Product Name: Pliaglis
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Crescita Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 18, 2021
Details:
The partnership relates to a novel oral formulation, developed under the project name ‘Nefecon’, of a potent and well-known active substance – budesonide – designed to target down regulation of IgA1 with a view to be disease modifying.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Product Name: Nefecon
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Calliditas Therapeutics AB
Deal Size: $115.0 million Upfront Cash: $24.0 million
Deal Type: Partnership July 21, 2021
Details:
As a result of agreement, patients in Germany are now able to access GMP-certified quality medical cannabis from STADA through local pharmacies under the brand – CannabiSTADA (cannabidiol), distributed through STADAPHARM, a direct subsidiary of STADA.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Gastroenterology Product Name: CannabiStada
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: MediPharm Labs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
